Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 28

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
 dated January 27, 2025, to purchase up to 3,000,000
additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.
On February 18, 2025, the underwriters exercised their option in full to purchase an additional 3,000,000 Units at a purchase price of
$10.00 per Unit, generating additional gross proceeds of $30,000,000.

The
underwriters were entitled to a cash underwriting discount of $0.05 per Unit, or 0.5% of the gross proceeds of the Initial Public Offering,
or $1,000,000 in the aggregate (or up to $1,150,000 if the over-allotment option is exercised in full), paid at the closing of the Initial
Public Offering and the $150,000 was paid on the closing of the over-allotment option. In addition, the underwriters are entitled to
a deferred fee of $0.30 per Unit, or 3.0% of the gross proceeds of the Initial Public Offering, or $6,900,000 in the aggregate,
of which 25.0% will be adjusted net of redemptions (i.e., for purposes of calculating the deferred underwriting commission net of redemptions,
25.0% of the deferred underwriting commissions will determined by the dollar amount that is product of (i) 3.0% multiplied by the product
of the number of unredeemed public shares, multiplied by $10.00 and (ii) 25.0%). The deferred fee becomes payable to the underwriters
from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms
of the underwriting agreement. In addition, the Company agreed to issue the underwriters 230,000 ordinary shares, denoted as representative
shares.

NOTE
7 — SHAREHOLDERS’ DEFICIT

Preference
Shares — The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share
with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of
directors. As of September 30, 2025 and December 31, 2024, there were no preference shares issued or outstanding.

Ordinary
Shares